Form 4: BioCardia Director Bill Facteau Reports Stock Option Grant

Director Bill Facteau reports the acquisition of stock options in BioCardia, Inc.

Summary

• Bill Facteau, a director of BioCardia, Inc. (BCDA), reported a transaction on October 11, 2024.
• Facteau acquired stock options to purchase 829 shares of common stock at an exercise price of $2.65.
• The options vest 100% on the one-year anniversary of the grant date, contingent upon continued service.
• Following the transaction, Facteau directly owns 3,729 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The grant of options can be seen as a positive sign of aligning interests, but it's a routine event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of one year is typical, ensuring continued service and commitment from the recipient.
• The exercise price is usually set at or above the market price at the time of the grant.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, Form 4, BioCardia, BCDA, director, Facteau, beneficial ownership, derivative securities